FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jon Weidanz

Research Profile

Anatomy

Chemicals & Drugs

Living Beings

Physiology

Procedures

Flow Cytometry

Disorders

Co-author Network

Publications

TOP 3
Rinki Jain; Maciej M Markiewski; Amit Rawat; Bhavna Verma; Jon A Weidanz
Antitumor activity of a monoclonal antibody targeting major histocompatibility complex class I-Her2 peptide complexes.
Jon A Weidanz; Bhavna Verma; Oriana Hawkins; William H Hildebrand
TCR-like biomolecules target peptide/MHC Class I complexes on the surface of infected and cancerous cells.
Jon A Weidanz; William H Hildebrand
Expanding the targets available to therapeutic antibodies via novel disease-specific markers.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jon Weidanz (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Rinki Jain; Maciej M Markiewski; Amit Rawat; Bhavna Verma; Jon A Weidanz
Antitumor activity of a monoclonal antibody targeting major histocompatibility complex class I-Her2 peptide complexes.
Journal of the National Cancer Institute 2013;105(3):202-18.
2011: Jon A Weidanz; Bhavna Verma; Oriana Hawkins; William H Hildebrand
TCR-like biomolecules target peptide/MHC Class I complexes on the surface of infected and cancerous cells.
International reviews of immunology 2011;30(5-6):328-40.
2011: Jon A Weidanz; William H Hildebrand
Expanding the targets available to therapeutic antibodies via novel disease-specific markers.
International reviews of immunology 2011;30(5-6):312-27.
2011: Oriana Hawkins; Bhavna Verma; Stan A Lightfoot; Rinki Jain; Amit Rawat; Sandy McNair; Shannon Caseltine; Aleksandar Mojsilovic; Priyanka Gupta; Francisca A Neethling; Othon Almanza; William C Dooley; William H Hildebrand; Jon A Weidanz
An HLA-presented fragment of macrophage migration inhibitory factor is a therapeutic target for invasive breast cancer.
Journal of immunology (Baltimore, Md. : 1950) 2011;186(11):6607-16.
2010: Raktima Bhattacharya; Yan Xu; Md Ashequr Rahman; Pierre-Olivier Couraud; Ignacio Romero; Babette B Weksler; Jon A Weidanz; Ulrich Bickel
A novel vascular targeting strategy for brain-derived endothelial cells using a TCR mimic antibody.
Journal of cellular physiology 2010;225(3):664-72.
2010: Bhavna Verma; Oriana E Hawkins; Francisca A Neethling; Shannon L Caseltine; Sherly R Largo; William H Hildebrand; Jon A Weidanz
Direct discovery and validation of a peptide/MHC epitope expressed in primary human breast cancer cells using a TCRm monoclonal antibody with profound antitumor properties.
Cancer immunology, immunotherapy : CII 2010;59(4):563-73.
2009: Nikhil M Vad; Garret Yount; Dan Moore; Jon A Weidanz; Majid Y Moridani
Biochemical mechanism of acetaminophen (APAP) induced toxicity in melanoma cell lines.
Journal of pharmaceutical sciences 2009;98(4):1409-25.
2009: Lloyd F Alfonso; Kalkunte S Srivenugopal; Thiruma V Arumugam; Thomas J Abbruscato; Jon A Weidanz; G Jayarama Bhat
Aspirin inhibits camptothecin-induced p21CIP1 levels and potentiates apoptosis in human breast cancer cells.
International journal of oncology 2009;34(3):597-608.
2008: Yuefei Yu; Petra Pilgrim; Wei Zhou; Nicoletta Gagliano; E Eldo Frezza; Marjorie Jenkins; Jon A Weidanz; Joseph Lustgarten; Martin Cannon; Klaus Bumm; Everardo Cobos; W Martin Kast; Maurizio Chiriva-Internati
rAAV/Her-2/neu loading of dendritic cells for a potent cellular-mediated MHC class I restricted immune response against ovarian cancer.
Viral immunology 2008;21(4):435-42.
2008: Maurizio Chiriva-Internati; Jon A Weidanz; Yuefei Yu; Eldo E Frezza; Marjorie R Jenkins; Ronald C Kennedy; Everardo Cobos; W Martin Kast
Sperm protein 17 is a suitable target for adoptive T-cell-based immunotherapy in human ovarian cancer.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2008;31(8):693-703.
2008: Francisca A Neethling; Venky Ramakrishna; Tibor Keler; Rico Buchli; Tito Woodburn; Jon A Weidanz
Assessing vaccine potency using TCRmimic antibodies.
Vaccine 2008;26(25):3092-102.
2007: Maurizio Chiriva-Internati; Fabio Grizzi; Jon A Weidanz; Raffaele Ferrari; Yu Yuefei; Beatriz Velez; Michael H Shearer; Devin B Lowe; Eldo E Frezza; Everardo Cobos; W Martin Kast; Ronald C Kennedy
A NOD/SCID tumor model for human ovarian cancer that allows tracking of tumor progression through the biomarker Sp17.
Journal of immunological methods 2007;321(1-2):86-93.
2007: Jon A Weidanz; Paolo Piazza; Heather D Hickman-Miller; David Woodburn; Tiffany Nguyen; Angela Wahl; Francisca A Neethling; Maurizio Chiriva-Internati; Charles Rinaldo; William H Hildebrand
Development and implementation of a direct detection, quantitation and validation system for class I MHC self-peptide epitopes.
Journal of immunological methods 2007;318(1-2):47-58.
2006: Angela Wahl; Jon A Weidanz; William Hildebrand
Direct class I HLA antigen discovery to distinguish virus-infected and cancerous cells.
Expert review of proteomics 2006;3(6):641-52.
2006: Jon A Weidanz; Tiffany Nguyen; Tito Woodburn; Francisca A Neethling; Maurizio Chiriva-Internati; William H Hildebrand; Joseph Lustgarten
Levels of specific peptide-HLA class I complex predicts tumor cell susceptibility to CTL killing.
Journal of immunology (Baltimore, Md. : 1950) 2006;177(8):5088-97.
2006: Vaughan Wittman; David Woodburn; Tiffany Nguyen; Francisca A Neethling; Stephen Wright; Jon A Weidanz
Antibody targeting to a class I MHC-peptide epitope promotes tumor cell death.
Journal of immunology (Baltimore, Md. : 1950) 2006;177(6):4187-95.
2006: Anjaneya P Chimalakonda; Donald L Montgomery; Jon A Weidanz; Imam H Shaik; Justin H Nguyen; John J Lemasters; Eiji Kobayashi; Reza Mehvar
Attenuation of acute rejection in a rat liver transplantation model by a liver-targeted dextran prodrug of methylprednisolone.
Transplantation 2006;81(5):678-85.
2005: Jon A Weidanz; Lynn M Jacobson; Rebecca J Muehrer; Arjang Djamali; Debra A Hullett; Jenifer Sprague; Maurizio Chiriva-Internati; Vaughan Wittman; Thomas J Thekkumkara; Bryan Becker
ATR blockade reduces IFN-gamma production in lymphocytes in vivo and in vitro.
Kidney international 2005;67(6):2134-42.
2004: Kimberlyn F Card; Shari A Price-Schiavi; Bai Liu; Elizabeth Thomson; Esperanza Nieves; Heather J Belmont; Janette Builes; Jin-an Jiao; Javier Hernandez; Jon A Weidanz; Linda Sherman; John L Francis; Ali Amirkhosravi; Hing C Wong
A soluble single-chain T-cell receptor IL-2 fusion protein retains MHC-restricted peptide specificity and IL-2 bioactivity.
Cancer immunology, immunotherapy : CII 2004;53(4):345-57.
2003: Maurizio Chiriva-Internati; Yong Liu; Jon A Weidanz; Fabio Grizzi; Hong You; Weiping Zhou; Klaus Bumm; Bart Barlogie; Jawahar L Mehta; Paul L Hermonat
Testing recombinant adeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24.
Blood 2003;102(9):3100-7.
2002: Seah H Lim; Phillip Periman; Panpit Klug; Jon A Weidanz; Vaughan Whitton; Maurizio Chiriva-Internati; Zhiqing Wang; Stephen Wright
Defining tumor antigens: mRNA, protein or cytotoxicity?
Trends in immunology 2002;23(5):236-7; author reply 237-8.
1998: Jon A Weidanz; Kimberlyn F Card; A Edwards; E Perlstein; Hing C Wong
Display of functional alphabeta single-chain T-cell receptor molecules on the surface of bacteriophage.
Journal of immunological methods 1998;221(1-2):59-76.
1998: C L Casipit; R Tal; Vaughan Wittman; P A Chavaillaz; Kathy Arbuthnott; Jon A Weidanz; Jin-an Jiao; H C Wong
Improving the binding affinity of an antibody using molecular modeling and site-directed mutagenesis.
Protein science : a publication of the Protein Society 1998;7(8):1671-80.